Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | HTR2B | P41595 | 5/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560051 | 1.00 | HTR2C (0.48) | HTR2CHTR2BCHRNB2CHRNA4 | |
| SCHEMBL943237 | 0.90 | TDO2 (0.48) | — | |
| Hydrochloric Acid SCHEMBL942643 | 0.89 | TDO2 (0.47) | — | |
| Hydrochloric Acid SCHEMBL2779881 | 0.89 | TDO2 (0.47) | — | |
| Hydrochloric Acid SCHEMBL28674299 | 0.85 | SLC6A4 (0.45) | HTR2CHTR2B | |
| Acetic Acid SCHEMBL4103124 | 0.81 | PAICS (0.46) | — | |
| SCHEMBL30843204 | 0.81 | FPR2 (0.49) | — | |
| SCHEMBL4828298 | 0.81 | CHRNB2 (0.47) | HTR2CHTR2BCHRNB2CHRNA4 | |
| SCHEMBL18077122 | 0.81 | TDO2 (0.52) | HTR2CHTR2BCHRNB2CHRNA4 | |
| SCHEMBL28671432 | 0.81 | TDO2 (0.52) | HTR2CHTR2BCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345063-B2 | Amides, preparation and therapeutic use as modulators of CCR-receptor activity | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| EP-1372651-B1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| US-20040122020-A1 | Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
| EP-1372651-A1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076457-A1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122020-A1 | Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity | CCR1, CCR4, CCR6 | HTR2C 600/4885HTR2B 643/4885CHRNB2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.